Inflammatory Bowel Disease PDF – Translating Basic Science into Clinical Practice
11.10 MB PDF
Inflammatory bowel disease research is changing. Progress in defining and treating these diseases is advancing in lock step with the furious pace of technological advances that continue to refine the tools of discovery. With sequencing of the entire genome completed, genetics research is providing direction for molecular and immunological in vivo and in vitro investigation, which in turn directs the development of targeted therapeutics. As translational investigation evolves, what is learned in clinical research is combined with what is learned in basic science research and is leading to a “personalized medicine” approach for managing inflammatory bowel diseases and is bringing the potential of prevention into view.
As Editors, our intention is that this book will provide insight along the entire continuum from basic science to clinical practice. The basic science chapters present findings in the context of what has already been established about the clinicopathological nature of the diseases. The clinical chapters describe the most effective applications of all available diagnostic and therapeutic approaches. This book reflects today’s trends toward globalism and is a truly international effort.We encouraged our contributors to editorialize and provide thought-provoking, progressstimulating content in their manuscripts. Now, more than ever, is the combination of all disciplines working in concert with the pharmaceutical industry key to the development of better treatments, with fewer side effects, and for predicting patient responses. As drugs become more specialized, it is vitally important to describe carefully patient populations both for study and for treatment. With ever increasing evidence that the inflammatory bowel diseases are heterogeneous disorders, drugs will likely only be effective in certain subpopulations of patients.
Above all, we hope that this book will stimulate future research to the point that achieving a diagnosis and development of a treatment plan will be directed by genetic, immunological and clinical markers of phenotypic distinctions.
We would like to express our sincere gratitude to each of the authors, our colleagues and partners, for nearly three decades of commitment to inflammatory bowel disease, and for their insightful, field-leading contributions. We would also like to acknowledge the commitment, patience and support of our publishers, Wiley-Blackwell, particularly Alison Brown, Adam Gilbert, Gill Whitley, Elisabeth Dodds and OliverWalter.
If you found this book helpful then please like, subscribe and share.